#freenome

[yaasita]

[skylarstark4826]

I loved this beautiful Fanart of the Wandavision ship of the Wandavision series of the characters of Vision and Wanda Maximoff (Scarlet Witch) together and especially because although I am aware that this beautiful fanart is clearly based on the Civil War movie I will not lie I really would have liked the fact that we had this same scene of Wanda and Vision and above all because I really love the fact that in the Vision he is tenderly holding Wanda's hand while telling her what he really wanted for her and also for his romantic feelings that he had for her... honestly

By the way, these beautiful Fanarts of them are not mine and the credits are not for me, but I will let you know that right here I am going to leave you the link of the real creator on Pinterest

[webstatus247dristi]

How to Get a Free Domain: A Complete Guide to Starting Your Online Journey

Getting your own domain name is the first step to building your online presence. Whether you're starting a blog, launching a small business, or creating a personal portfolio, a domain gives your project credibility. But what if you don't want to spend money upfront? Fortunately, there are several legitimate ways to get a domain name for free.

In this guide, we’ll walk you through the best options to get a free domain in 2025 and how to maintain it for long-term success.

What Is a Domain Name?

A domain name is your website’s address on the internet (like yourname.com). It allows people to access your site without needing to remember long IP addresses. Owning a domain gives you control over your brand, email addresses, and web presence.

How to Get a Free Domain Name

1. Free .np Domains in Nepal

If you’re a Nepali citizen, student, or business, you can register a .np domain for free at register.com.np.

Steps:

Search for available domains like yourname.com.np.

Upload required documents:

Citizenship or Passport for individuals

Business registration and PAN for organizations

Fill out the application and submit it

Wait 1–3 days for approval

This is perfect for local businesses and personal portfolios in Nepal.

2. Free Domains from Hosting Providers

Some hosting companies include a free domain for one year when you buy hosting services. This option is great if you're planning to build your site immediately.

Top Hosting Providers:

Bluehost – Trusted by WordPress

Hostinger – Budget-friendly with free SSL

Wix – Drag-and-drop builder + domain

While these aren’t 100% free (you pay for hosting), the bundled domain is a great deal.

3. Use Freenom for Free TLDs

Freenom offers free domains with extensions like .tk, .ml, .ga, .cf, and .gq. These are ideal for temporary projects or testing environments.

Pros:

Completely free

Easy to register

Cons:

Less professional

May not rank well in search engines

Use this only for short-term or hobby projects.

4. Free Subdomains for Beginners

Many platforms offer subdomains at no cost. These aren’t full domain names, but they work if you're just starting out.

Platforms:

WordPress.com → yourname.wordpress.com

Blogger → yourname.blogspot.com

GitHub Pages → yourname.github.io

Subdomains are best for beginners, students, or hobby bloggers who want to learn without investment.

Domain Monitoring Is Essential

Once you get your domain, keeping it active and secure is key. Downtime, DNS issues, or expired domains can hurt your site’s reputation and SEO.

Use tools like WebStatus247 Domain Monitoring to:

Monitor uptime

Get alerts on DNS changes

Avoid domain expiration

Monitoring ensures your domain stays live and trusted.

Tips for Choosing a Great Domain Name

Keep it short and memorable

Use keywords related to your niche

Avoid numbers and hyphens

Make sure it's easy to spell and pronounce

Check for social media availability too

A great domain boosts your brand’s visibility and trust.

Free vs Paid Domains: What’s Right for You?

FeatureFree DomainPaid DomainCost$0~$10–15/yearBrandingLimitedProfessionalSEO TrustLowerHigherOwnershipMay be restrictedFull control

Choose a free domain if you're experimenting or just starting out. Invest in a paid one for business or serious blogging.

Conclusion

Getting a free domain is a great first step toward launching your online identity. Whether you choose a .np domain, use Freenom, or start with a subdomain, make sure to keep your domain monitored and updated.

Ready to take action? Secure your domain today and monitor it with WebStatus247 to stay online 24/7.

[deadnamedblog]

Saw this picture

source :

I thought it was official art at first.

[visionaryvogues03]

The Role of Biotech Unicorns in Revolutionizing Cancer Therapy

In the ever-evolving healthcare landscape, few areas have seen more transformational growth than cancer therapy. While traditional pharmaceutical giants have long dominated oncology, a new class of players biotech unicorns is emerging as a major force reshaping how cancer is diagnosed, treated, and even prevented. These high-valuation startups are not only driving innovation but also challenging established norms in cancer care, bringing agility, novel technologies, and disruptive thinking to the forefront.

Today, cancer remains one of the leading causes of death in the United States, with the American Cancer Society estimating nearly 2 million new cases will be diagnosed in 2025. In this high-stakes environment, the need for groundbreaking solutions has never been greater. Biotech unicorns, companies valued at over $1 billion, are stepping up to meet this demand with pioneering approaches to cancer therapy.

Why Biotech Unicorns Matter in Cancer Therapy

Biotech unicorns bring a different mindset to the healthcare space. Unlike larger pharmaceutical firms, these companies are often more willing to take risks on experimental treatments, unproven technologies, and bold ideas that could redefine cancer therapy. They operate at the intersection of science, technology, and patient-centric innovation, offering fresh hope where traditional treatments have fallen short.

Take, for example, companies like Moderna and Grail. While Moderna gained widespread recognition during the COVID-19 pandemic for its mRNA technology, its research in cancer vaccines is progressing rapidly. Grail, another biotech unicorn, is working on early detection blood tests that could identify cancer before symptoms even appear. These innovations could shift the focus of cancer therapy from reactive treatment to proactive prevention.

Key Areas Where Biotech Unicorns Are Revolutionizing Cancer Therapy

[Source - Tempus]

1. Precision Medicine

One of the most significant advancements driven by biotech unicorns is in precision medicine—tailoring cancer therapy to the genetic profile of an individual patient. Startups like Tempus are using artificial intelligence and massive genomic databases to help doctors design personalized treatment plans. This approach not only increases effectiveness but also reduces the severe side effects often associated with traditional cancer treatments.

By analyzing vast amounts of genetic data, biotech unicorns are enabling a new generation of therapies that are more targeted and efficient, moving away from the "one-size-fits-all" model that has long dominated cancer care.

2. Immunotherapy Innovations

Immunotherapy has emerged as one of the most promising fields in cancer therapy, and biotech unicorns are leading the charge. Companies like Allogene Therapeutics are developing off-the-shelf CAR-T therapies, which modify a patient's immune cells to better recognize and attack cancer cells.

Unlike conventional treatments like chemotherapy and radiation, immunotherapy harnesses the body’s natural defenses. This not only offers a higher success rate for some types of cancer but also reduces the collateral damage to healthy tissues. Biotech unicorns are pushing the boundaries of immunotherapy by making it more accessible, scalable, and affordable.

3. Liquid Biopsies and Early Detection

Early detection is critical for successful cancer therapy, yet traditional methods like imaging and tissue biopsies can be invasive, costly, and slow. Biotech unicorns such as Grail and Freenome are developing liquid biopsy technologies—simple blood tests that can detect cancer in its earliest stages.

According to a report from the American Society of Clinical Oncology, early detection can increase five-year survival rates by as much as 90% for some cancers. The widespread adoption of liquid biopsies could fundamentally change cancer therapy by catching the disease when it is most treatable, drastically improving patient outcomes.

4. AI and Machine Learning in Oncology

Another arena where biotech unicorns are making waves is the use of artificial intelligence (AI) and machine learning. Companies like PathAI and Tempus are employing AI algorithms to better predict treatment responses, analyze pathology images, and discover new drug targets.

Integrating AI into cancer therapy allows for faster, more accurate diagnoses and the development of highly customized treatment plans. The potential cost savings and improved patient outcomes from AI-driven oncology solutions could have a profound impact on the U.S. healthcare system, making advanced cancer care more accessible to all.

The Business Dynamics Behind Biotech Unicorn Success

Biotech unicorns are flourishing in part because of robust investment trends. According to CB Insights, biotech startups attracted over $45 billion in global funding in 2024, with a substantial portion directed toward oncology-focused firms. This influx of capital enables these companies to invest heavily in research and development, accelerate clinical trials, and fast-track promising therapies to market.

Moreover, the U.S. regulatory environment has become increasingly supportive of innovative cancer therapies. Programs like the FDA's Breakthrough Therapy Designation and Accelerated Approval pathways have streamlined the process for bringing groundbreaking cancer treatments to patients faster.

Collaborations between biotech unicorns and larger pharmaceutical companies also play a pivotal role. These partnerships combine the innovation and agility of startups with the resources and global reach of established players, creating a synergistic model for revolutionizing cancer therapy.

Challenges Ahead for Biotech Unicorns in Cancer Therapy

Despite the optimism, biotech unicorns face formidable challenges. Bringing a new cancer therapy from lab to market remains an expensive, complex, and high-risk endeavor. The average cost to develop a new oncology drug can exceed $2.5 billion and take over a decade.

There are also ethical considerations around access and affordability. Will revolutionary cancer therapies be available only to the wealthy, or can they be scaled for broader accessibility? Biotech unicorns must navigate these questions carefully to ensure that their innovations do not inadvertently widen healthcare disparities.

Moreover, scientific breakthroughs do not guarantee commercial success. Regulatory hurdles, clinical trial failures, and unforeseen side effects can derail even the most promising cancer therapies. The pressure to deliver both medical miracles and financial returns is intense.

Looking Ahead: The Future of Cancer Therapy

As biotech unicorns continue to mature, their influence on cancer therapy will only grow stronger. Emerging areas like gene editing, nanomedicine, and personalized cancer vaccines offer tantalizing possibilities for even more precise and effective treatments.

Additionally, the integration of wearable technologies, real-time patient monitoring, and decentralized clinical trials will enable more patient-centric approaches to cancer therapy. Biotech unicorns are well-positioned to capitalize on these trends by staying nimble, innovative, and relentlessly focused on unmet needs.

The future of cancer therapy is being shaped right now in startup labs and incubators across the U.S.—places where ambition meets urgency, and where the next wave of life-saving treatments is being born.

Conclusion

The rise of biotech unicorns represents a pivotal shift in the world of cancer therapy. These nimble, innovative companies are not just complementing traditional pharmaceutical efforts; they are redefining what’s possible in oncology. By bringing cutting-edge science, AI-driven insights, and a bold entrepreneurial spirit to healthcare, biotech unicorns are giving new hope to millions of patients and transforming the future of medicine.

As we look toward a new era in cancer therapy, one thing is clear: the next breakthroughs will likely come not from the boardrooms of legacy firms but from the vibrant, fast-moving world of biotech startups.

Uncover the latest trends and insights with our articles on Visionary Vogues

[researchyblog]

Minimal Residual Disease Testing: Shaping the Future of Cancer Monitoring and Personalized Treatment

Minimal Residual Disease Testing Market Size & Forecast

The minimal residual disease (MRD) testing market is experiencing remarkable growth, propelled by several key factors. The rising incidence of cancer globally has heightened the need for more accurate monitoring and relapse prevention strategies. MRD testing is becoming increasingly vital, especially in hematological malignancies, where it helps track the effectiveness of treatments and detect early signs of recurrence. The high recurrence rates of certain cancers have made regular MRD monitoring essential in oncology care. Additionally, increased investments and funding in MRD test development are further accelerating market expansion. Emerging economies offer significant growth potential, with the rising adoption of personalized treatments and targeted therapies opening new avenues. The application of MRD testing is now expanding into solid tumors, generating further opportunities for market players.

Get Sample Copy @ https://www.meticulousresearch.com/download-sample-report/cp_id=6068?utm_source=Blog&utm_medium=Product&utm_campaign=SB&utm_content=28-04-2025

Minimal Residual Disease Testing Market Growth Drivers

Growing Cancer Incidence

The increasing awareness around cancer screening and early diagnosis is resulting in cancers being detected at earlier stages, leading to improved survival rates supported by new treatment advancements. However, cancer survivors face a constant risk of relapse, making regular MRD monitoring critical to detect any signs of cancer's return. According to the International Agency for Research on Cancer, new cancer cases are projected to surge from 19.2 million in 2020 to 24.5 million by 2030. This rising burden of cancer significantly boosts the demand for MRD testing across various applications.

Investments and Funding for Minimal Residual Disease Testing

The MRD testing field has gained substantial traction due to the global cancer burden and the focus on enhancing patient outcomes. Companies developing MRD tests are increasingly securing large investments to further research and commercialization efforts. For example, in February 2024, Freenome Holdings, Inc. received a $254 million investment to advance its single-cancer and multi-cancer early detection tests built on a multiomics platform. This platform is also being evaluated for MRD applications. Similarly, in September 2023, Adela, Inc. raised $48 million to support its technology platform for MRD monitoring. Public and private funding is playing a crucial role in propelling innovation in this sector.

Minimal Residual Disease Testing Market Trends

Emergence of Digital PCR

Digital PCR (dPCR) has emerged as a breakthrough technology in MRD testing. Unlike traditional PCR methods, dPCR partitions samples into thousands of individual reactions, enhancing the precision of nucleic acid quantification. This heightened sensitivity is critical for detecting very low levels of residual disease in patients, particularly those with blood cancers. Additionally, dPCR offers a simplified workflow with reduced hands-on time, making it more practical for clinical adoption. As technology continues to evolve, dPCR is expected to become a standard method for MRD testing, offering higher accuracy and real-time monitoring capabilities.

Single-cell Multiomics and Artificial Intelligence in Minimal Residual Disease Testing

The use of single-cell multiomics is another transformative trend in MRD testing. By simultaneously assessing genetic and immunophenotypic characteristics at the single-cell level, researchers and clinicians can obtain a comprehensive view of residual disease. These detailed molecular profiles provide deeper insights into cancer biology, helping identify new markers for early recurrence detection. Furthermore, artificial intelligence (AI) and advanced bioinformatics are revolutionizing data analysis. AI algorithms are capable of identifying subtle patterns in complex genetic datasets, enhancing the accuracy of MRD detection and aiding in better prediction of patient outcomes. With these technological advancements, the future of MRD testing promises even greater precision and personalization.

Minimal Residual Disease Testing Market Opportunities

Growing Use of MRD Testing in Solid Tumors

Historically, MRD testing has been heavily used in blood cancers, but its application in solid tumors is expanding rapidly. Advances in research have highlighted the potential of MRD testing in informing treatment decisions for patients with solid tumors. Diagnostic companies are actively launching MRD tests tailored for solid tumors, reflecting the growing demand. For instance, in October 2023, Personalis, Inc. introduced NeXT Personal Dx, a clinical MRD test designed for lung and breast cancer patients. By detecting small amounts of residual disease after surgery or therapy, MRD testing enables more personalized follow-up strategies, ultimately improving patient outcomes. As clinical trials and research progress, the use of MRD testing in solid tumors is expected to open significant new market opportunities.

Minimal Residual Disease Testing Market Analysis: Key Findings

By Offering: Assays & Reagents to Dominate in 2024

Based on offerings, the MRD testing market is divided into assays & reagents, instruments, and software & services. In 2024, assays & reagents are anticipated to command the largest share, accounting for 76.7% of the market. The high share is attributed to the repeated usage of these products, ongoing R&D in oncology leading to new test developments, and a rising trend among players to introduce innovative assays. Moreover, this segment is forecasted to grow at a robust CAGR of 15.4% from 2024 to 2031, driven by increasing cancer rates and expanding applications of MRD testing in clinical trials and patient monitoring.

By Technology: Flow Cytometry to Lead in 2024

On the technology front, flow cytometry is expected to dominate the MRD testing market in 2024 with a share of 42.7%. Flow cytometry’s real-time data capabilities, affordability compared to next-generation sequencing (NGS), and widespread availability are key factors behind its dominance. Although flow cytometry is leading, polymerase chain reaction (PCR) technology is anticipated to post the fastest growth during the forecast period, with a projected CAGR of 16.6%. PCR’s high specificity and molecular-level detection abilities make it a critical tool for early interventions in cancer management.

Get Full Report @ https://www.meticulousresearch.com/product/minimal-residual-disease-testing-market-6068?utm_source=Blog&utm_medium=Product&utm_campaign=SB&utm_content=28-04-2025

By Application: Blood Cancers Segment to Dominate in 2024

When analyzed by application, MRD testing for blood cancers is set to hold the larger market share in 2024. The increasing incidence of blood cancers, coupled with the availability of advanced MRD testing solutions and greater focus on precision oncology, are major drivers. This segment is also projected to record the highest CAGR through 2031, as MRD monitoring becomes an integral part of managing blood cancers such as leukemia, lymphoma, and multiple myeloma.

By Sample Type: Blood Sample Testing to Lead in 2024

By sample type, blood samples are expected to dominate the MRD testing market in 2024. The simplicity and noninvasive nature of blood collection make it a preferred option over bone marrow or other sample types. Additionally, blood-based MRD testing ensures better patient compliance for regular monitoring, further boosting its adoption. This segment is also poised to register the highest growth rate throughout the forecast period.

By Customer Type: Pharmaceutical & Biopharmaceutical Companies to Lead

Pharmaceutical and biopharmaceutical companies are projected to account for the largest share of the MRD testing market by customer type in 2024. The high adoption of MRD testing in clinical trials for oncology therapies, along with heavy investments in cancer drug development, underpin the segment’s dominance. Moreover, regulatory encouragement for MRD inclusion in trials is driving adoption among pharmaceutical players. This segment is expected to maintain the highest growth trajectory in the coming years.

Geographical Analysis: North America to Dominate, Asia-Pacific to Grow Fastest

In 2024, North America is forecasted to account for 38.8% of the MRD testing market, with the U.S. being the major contributor. Factors such as rising cancer incidence, government funding, and the presence of key market players drive North America’s leadership. However, the Asia-Pacific region is expected to register the highest CAGR of 15.5% through 2031. Improving healthcare infrastructure, growing cancer prevalence, rising interest in personalized therapies, and expanding cancer screening initiatives make Asia-Pacific an attractive market for MRD testing solutions.

Minimal Residual Disease Testing Market: Key Companies

The MRD testing market is highly competitive and innovation-driven. Key players include Illumina, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Natera Inc, Bio-Rad Laboratories, Inc., Adaptive Biotechnologies Corporation, Sysmex Corporation, Integrated DNA Technologies, Inc., Twist Bioscience Corporation, and Invivoscribe Inc. These companies are driving market growth through strategic partnerships, product launches, and investments in advanced technologies.

Minimal Residual Disease Testing Industry Overview: Latest Developments

Recent industry moves include Bio-Rad Laboratories’ collaboration with Allegheny Health Network for droplet digital PCR (ddPCR) MRD monitoring across various cancer types in April 2024. In addition, Bio-Rad also launched the QX600 Droplet Digital PCR System in 2023. Thermo Fisher Scientific expanded its portfolio in August 2022 with the launch of the NGS-based Myeloid MRD Assay. These developments reflect the dynamic nature of the MRD testing market and the ongoing push for technological innovation.

Get Sample Copy @ https://www.meticulousresearch.com/download-sample-report/cp_id=6068?utm_source=Blog&utm_medium=Product&utm_campaign=SB&utm_content=28-04-2025

[allupdatesofmarket]

Global AI in Diagnostics and Drug Discovery Market Insights: Size, Share, and Industry Outlook to 2033

AI in Diagnostics and Drug Discovery Market

The global AI in diagnostics and drug discovery market size was valued at USD 7.34 billion in 2024 and is estimated to reach USD 64.62 billion by 2033, growing at a CAGR of 25.43% during the forecast period (2025–2033).

AI in Diagnostics and Drug Discovery Market Overview:

The AI in Diagnostics and Drug Discovery Market Report delivers in-depth insights into a market spanning multiple industries, offering forecasts and trend analyses for the period from 2024 to 2033. The study investigates significant themes such as product innovation, adoption rates, pricing strategies, and regional market penetration by combining a plethora of quantitative data with expert opinion. To contextualize market fluctuations, macroeconomic factors such as GDP growth and socioeconomic indices are also considered. AI in diagnostics and drug discovery refers to the integration of artificial intelligence technologies into the healthcare and pharmaceutical industries to enhance medical diagnostics and accelerate the drug development process. In diagnostics, AI systems use machine learning, natural language processing, and computer vision to analyze medical data, such as imaging, patient records, and genetic information, improving diagnostic accuracy and speed. Sectors that use the goods or services, leading market players, and changing client preferences are all essential topics of discussion. This research thoroughly examines the competitive landscapes, regulatory impacts, and technological changes that influence the market. The AI in Diagnostics and Drug Discovery Market Report, which is separated into well-defined sections, delivers practical business insights to stakeholders from a wide range of political, cultural, and economic backgrounds.

Get Sample Research Report: https://marketstrides.com/request-sample/ai-in-diagnostics-and-drug-discovery-market

AI in Diagnostics and Drug Discovery Market Growth And Trends

The sector is undergoing a substantial shift, fueled by many AI in Diagnostics and Drug Discovery Market developments that are changing its future. These significant developments are critical to follow, as they may redefine operations and strategies. Digital Transformation: As digital technologies advance, data-driven solutions improve consumer interaction and optimize operations. Customer Preferences: The increased emphasis on convenience and personalization is driving businesses to offer customized products. Regulatory Changes: As compliance standards and policies tighten, businesses are being required to adapt swiftly in order to remain competitive.

Top Key Player in AI in Diagnostics and Drug Discovery Market

IBM Watson Health

Google Health

Microsoft

Siemens Healthineers

GE Healthcare

Philips Healthcare

NVIDIA

Tempus

PathAI

BenevolentAI

Insilico Medicine

Aidoc

Freenome

DeepMind Technologies

Cerner Corporation

This section provides a SWOT analysis of the AI in Diagnostics and Drug Discovery Market market's leading participants, with a focus on the top three to five organizations. It explores their primary strategies, current priorities, competitive challenges, and potential market expansion areas, highlighting their benefits, drawbacks, opportunities, and risks. Furthermore, the company list can be customized to meet the preferences of the client. In the competitive environment section, we rank the top five organizations and look at recent developments such as alliances, mergers, acquisitions, and product launches. Their geographical presence and market significance are also examined, as are their AI in Diagnostics and Drug Discovery Market market share, growth potential, and contributions to overall market growth, using the Ace matrix criteria.

Browse Details of AI in Diagnostics and Drug Discovery Market with TOC: https://marketstrides.com/report/ai-in-diagnostics-and-drug-discovery-market

AI in Diagnostics and Drug Discovery Market :Segmentation

By Deployment Mode

On-premises

Cloud-based

By Technology

Machine Learning (ML)

Natural Language Processing (NLP)

Computer Vision

Generative AI

By Application

Diagnostics

Drug Discovery

Personalized Medicine

Clinical Trials

By End-User

Healthcare Providers

Pharmaceutical Companies

Research Institutes

Contract Research Organizations (CROs)

Research Methodology

The research technique employed for this study demonstrates the analytical team's extensive work, as it uses data from reliable sources to ensure accuracy and depth. The methodology includes the following: Primary research is speaking with industry professionals directly via surveys, interviews, and consultations to gain firsthand knowledge. This is complemented by information from government publications, annual reports, and corporate news releases. Secondary research is a thorough examination of the social, political, and economic factors influencing the market, utilizing market studies, trade magazines, industry reports, and scholarly study. Data validation is the process of thoroughly cross-checking and verifying collected data with expert and analyst input to ensure that the results are legitimate and reliable.

Regional Analysis of the AI in Diagnostics and Drug Discovery Market

The AI in Diagnostics and Drug Discovery Market Research Report provides a detailed examination of the AI in Diagnostics and Drug Discovery Market across various regions, highlighting the characteristics and opportunities unique to each geographic area.

North America

Europe

Asia-Pacific

Latin America

The Middle East and Africa

Buy Now:https://marketstrides.com/buyNow/ai-in-diagnostics-and-drug-discovery-market

About Us:

Market Strides is a global publisher and aggregator of economic, equity, market, and database directories. Our collection is extensive, including nearly all industrial sectors, as well as every industry category and subclass. Our market research reports include market sizing and competition analysis, as well as potential futures and growth determinants. The business uses data analytics and research to assist clients with due diligence, product expansion, plant setup, acquisition intelligence, and other aims.

Contact Us: sales@marketstrides.com

[restart2007]

Freenom - A Name for Everyone

[healthcaremarketanalysis]

Liquid Biopsy Market worth $11.3 billion by 2029

Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™.

Liquid Biopsy Market Trends

Download an Illustrative overview:

Browse in-depth TOC on "Liquid Biopsy Market"

406 - Tables

56 - Figures

343 - Pages

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

Liquid Biopsy Market Dynamics:

Drivers:

Rising incidence and prevalence of cancer

Cancer awareness initiatives undertaken by global health organizations

Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

Lower sensitivity of certain liquid biopsy procedures

Opportunities:

Growing significance of companion diagnostics

Growth opportunities in emerging countries

Challenge:

Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

The break-up of the profile of primary participants in the liquid biopsy market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report:

Recent Developments of Liquid Biopsy Industry:

In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory.

In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

In November 2023, Illumina, Inc. (US) launched its TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2.

In April 2023, QIAGEN (Netherlands) launched the QIAseq Targeted cfDNA Ultra Panels, enabling researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries ready for NGS in less than eight hours.

In January 2022, Illumina, Inc. (US) partnered with Boehringer Ingelheim (Germany). This partnership was aimed to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Liquid Biopsy Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland).

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

[digitaltariq]

ARK says it is a distinctive time to speculate

ARK Make investments's chief futurist lists 5 teams that ought to give tech buyers an edge.Based on Brett Winton, robotics, synthetic intelligence, multi-omics sequencing, public blockchain and vitality storage are key areas as a result of they're all getting into {the marketplace} on the identical time."We imagine that it is a distinctive time in technological financial historical past," he instructed CNBC's "ETF Edge" this week.Winton collaborates with ARK Make investments CEO Cathie Wooden to take care of the ARK Enterprise Fund (ARKVX), which permits buyers to purchase into the non-public know-how area.Based on the agency's web site, the purpose of the fund is to make enterprise capital choices of modern areas available in the market accessible to particular person buyers. As of April 10, it exhibits the fund's prime holdings embody Epic Video games, recognized for on-line online game Fortnite, and biotech corporations Freenome and Relation Therapeutics."Our emphasis is that we're investing in innovation over the long run and going to help administration groups," stated Winton.He contends it is a technique that is typically not prioritized."That is an actual problem loads of public market buyers haven't got that long-term view," Winton added.The ARK Enterprise Fund is down greater than 7% to date this 12 months. Nonetheless, it is up nearly 39% % over the previous 52-weeks.

Don’t miss these exclusives from CNBC PRO

Read the full article

[kennak]

記事とは関係ありませんが、.tkを見ると色々な思い出が甦ります。 国際クレジット カード (VISA/Mastercard) はおろか、銀行口座も持たない子供にとって、自分の名前を使って Web サイトをオンラインに公開する唯一の方法は dot.tk です。 私はクラスメート、学校、家族向けに .tk を使用して数え切れないほどの Web サイトを作成しました。

Cloudflare、Freenom .tkのシャットダウンでドメインの22%を失う | ハッカーニュース

[ericvanderburg]

Cloudflare Loses 22% Of Its Domains In Freenom .tk Shutdown

http://i.securitythinkingcap.com/T4JF5m

[hackernewsrobot]

Cloudflare loses 22% of its domains in Freenom .tk shutdown

https://www.netcraft.com/blog/cloudflare-loses-22-of-its-domains-in-freenom-tk-shutdown/

[forestduck]

Nov 3, 2012 - Freenom World is a fast and anonymous Public DNS resolver.

[vinhjacker1]

Is it possible to make an e-commerce site with PHP and MySQL for free?

Yes, it is possible to create an e-commerce site using PHP and MySQL for free. PHP is a server-side scripting language, and MySQL is a popular open-source relational database management system. Together, they provide a powerful and cost-effective solution for building dynamic websites, including e-commerce platforms.

To get started, you'll need the following:

Web Hosting: There are several free hosting providers that support PHP and MySQL. Examples include 000webhost, InfinityFree, and Heroku. Keep in mind that free hosting may have limitations, such as bandwidth and storage restrictions.

Domain Name: You can either use a free subdomain provided by the hosting service or register a free domain from services like Freenom.

Code Editor: You can use any text editor for writing PHP code. Popular choices include Visual Studio Code, Sublime Text, or Atom.

PHP and MySQL Knowledge: Basic understanding of PHP and MySQL is necessary for developing the backend of your e-commerce site.

Here's a simplified overview of the steps you might take:

1. Set Up a Development Environment

Download and install a local server environment like XAMPP or WampServer to develop your site locally before deploying it.

2. Design Your Database

Plan and create a MySQL database to store product information, user data, and order details.

3. Write PHP Code

Develop the backend logic using PHP to handle user authentication, product management, and order processing.

4. Create Frontend

Design the frontend using HTML, CSS, and JavaScript to create a user-friendly interface. You may also consider using a front-end framework like Bootstrap.

5. Implement E-commerce Features

Add features such as product listing, product details, shopping cart, and checkout functionality.

6. Testing

Test your e-commerce site thoroughly to ensure that it works as expected and is secure.

7. Deploy

Once you're satisfied with your site, upload the files to your hosting provider.

[linn-zy]

Yes. Mooncloud wrote on her FB; "My website is down, I know. It's not my fault, it's because of the DNS server. All sites ending in TK has stopped working during the past month. The site is still online on the original server though. If this post works I will post link in comments."

And

"my website is currently hosted by my work server so you can still visit at withchoholic.tk until Freenom gives me my URLs back. again."

do you know what happened to witcholic

No - you're thinking of with-o-holics website, right? I checked now and it's gone :( Anyone else know anything?